China
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Learn more about how China’s biopharmas are going global by working with dependable and trustworthy companion diagnostics partners.
China's Duality Biologics, founded in 2020, has developed two-thirds of its clinical-stage antibody-drug conjugates by combining antibodies acquired from domestic peers with its proprietary linker-payload platform.
An employee of Astellas in China first detained 17 months ago on suspicion of espionage has been formally indicted and now faces trial.
Being the Chinese biotech’s backbone asset in the autoimmune disease area, telitacicept, a BlyS/APRIL dual targeting fusion protein, has hit its target in a China-only Phase III study in generalized myasthenia gravis. The candidate is also being investigated in global Phase III trials in systemic lupus erythematosus and Sjögren's syndrome.
If closed successfully, the traditional producer of active pharmaceutical ingredients and generic drugs will scoop up the world’s second advanced KRAS G12D-targeting T-cell receptor (TCR) T cell therapy candidate, as well as an EGFR variant III-targeting chimeric antigen (CAR) receptor T-cell agent. Out-licensing efforts are already under way.
July was an active month for deals between Chinese biopharma firms, as some looked to build their pipelines and others for partners to help commercialize products moving to market. Two ADCs, a GLP-1R/GIPR fusion protein and an IL-4Rα antibody were among the assets changing hands.
RNK Pharma founder and CEO Yaning Wang joins Brian Yang to discuss the latest biopharma stimulus policies offered by Shanghai and the globalization of China biotech. Dexter Yan also talks about China biotech initial public offering trends in the first half of this year.
Amid stricter regulatory reviews of applications for IPOs across all sectors, such offerings in biotech have been in hiatus on the Chinese mainland in 2024 to date. Meanwhile, three bioventures raised a combined $217.8m as they floated on the Hong Kong Stock Exchange in the first half.
Everything seemed to be aligned for success, but shares in leading Chinese antibody developer RemeGen recently dropped by nearly 40%, reflecting a range of internal and external likely factors.
The global battle of the blockbuster obesity drugs appears set to come to China with the approval of Lilly's Mounjaro, although domestic competitors are fast catching up.
One Chinese biotech executive is entertaining hopes of China’s domestic market for novel drugs growing to CNY300bn ($41bn). However, the country’s public payer spent just CNY90bn on such products in 2023 and is expected to increase expenditure to more than CNY100bn this year.
A reported buyout bid for Legend Biotech has delivered a much needed shot of confidence to the Chinese biotech sector, despite not being confirmed. Amid a shifting environment, Hengrui also sees globalization as essential to its future.
Growing geopolitical tensions and a slowing Chinese economy are among the topmost concerns for global business leaders across sectors, a McKinsey study has shown. Separately, in pharma, the BIOSECURE Act continues to occupy centre stage with US House Speaker Johnson recently pledging to push China-targeted legislation before House elections in November
In this week's podcast edition of Five Must-Know Things: Q1’s top 10 drugs; Pfizer’s R&D leadership succession; Lilly bolsters IBD pipeline; first half deal volume up but value down; and EU firms’ China sentiment plummets.
Having initiated China-only Phase III trials with three oncology and autoimmune drug candidates, HUTCHMED is looking for partnerships to take the molecules to the clinic in the US.
AI specialist METiS Pharmaceuticals raked in $100m in a series C round, while four other deals backed by venture capital and private equity firms crossed the CNY100m ($14m) mark in the latest fundraisings by Chinese biopharma companies.
China's deepening economic downturn is impacting foreign business confidence in China, while recent high-profile events have created uncertainties around the go-global push by Chinese pharma firms, at a time when this has become critical to their very survival.